Twenty-four-month treatment outcomes in treatment-naive eyes receiving 2 mg aflibercept for macular edema secondary to central retinal vein occlusion

Purpose: To report 24-month outcomes of anti-vascular endothelial growth factor (VEGF) treatment 2 mg Aflibercept in patients with cystoid macular edema (CME) due to central retinal vein occlusion (CRVO) in routine clinical practice. Methods: In this observational single-center study, 46 treatment-naive CRVO eyes with CME that completed aflibercept treatment over 24 months were analyzed. In addition, eyes were categorized according to baseline visual acuity (VA). The primary outcome was the mean change in VA from baseline to 24 months. Secondary outcomes included changes in central subfield thickness (CST), intraocular pressure, median number of injections and visits, time to additional laser therapy, and adverse events. Results: Overall, mean VA and CST (mean ± standard deviation) changed by +24 (±28) letters and −234 (±242) µm, respectively, from baseline to 24 months. With a median of 18 visits, 13 injections were administered. Eyes with a VA of ≤35 letters at baseline showed a mean VA increase of 34 letters. Eyes with a baseline VA between 35 and 70 letters had a mean change of + 13 letters. In eyes with a baseline VA of ≥70 letters, the mean improved by 8 letters. Conclusion: Anti-VEGF treatment with 2 mg Aflibercept achieves notable visual improvements in eyes with macular edema secondary to CRVO within 2 years. In particular, patients with poor baseline VA experience a substantial increase in vision due to intensive Aflibercept injections.